Marco Iannetta

Marco Iannetta
  • MD, PhD
  • Research Associate at University of Rome Tor Vergata

About

3
Publications
338
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
60
Citations
Introduction
Current research interests: infectious diseases in immunocompromised host. Host-pathogen interaction. Immunology of infectious diseases. Methods and techniques: clinical and translational approach; flow cytometry; ELISA; molecular biology; cell culture.
Current institution
University of Rome Tor Vergata
Current position
  • Research Associate
Additional affiliations
November 2019 - present
University of Rome Tor Vergata
Position
  • Research Associate
Description
  • Infectious Diseases in immunocompromised hosts
April 2016 - October 2019
Istituto Nazionale per le Malattie Infettive "L.Spallanzani"
Position
  • Infectious Disease Specialist
Description
  • Infectious Diseases, Tropical Diseases, Arboviral infections
September 2015 - March 2016
Sapienza University of Rome
Position
  • PostDoc Position
Education
October 2009 - October 2012
Sapienza University of Rome
Field of study
  • Immunology and Infectious Diseases
October 2005 - October 2009
Sapienza University of Rome
Field of study
  • Infectious Diseases
September 1999 - September 2005
Sapienza University of Rome
Field of study
  • Medical School

Publications

Publications (3)
Article
Full-text available
Markers of JC polyomavirus (JCPyV) activity can be used to evaluate the risk of progressive multifocal leukoencephalopathy (PML) in treated multiple sclerosis (MS) patients. The presence of JCPyV DNA and microRNA (miR-J1-5p), the anti-JCV index and the sequence of the non-coding control region (NCCR) in urine and plasma were determined in 42 MS sub...
Article
Full-text available
Available therapeutic options against carbapenem-resistant Klebsiella pneumoniae (CR-Kp) are limited because of the high level of resistance to other antimicrobial classes including polymyxins. The double-carbapenem regimen has been recently considered a possible therapeutic strategy. In the present study, we evaluated the in vitro bactericidal and...

Network

Cited By